Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Development and Use of Cripto-1 as a Biomarker and Treatment for Neurodegenerative Disease Only written comments and/or applications for a license, which are received by the NIH Office of Technology Transfer on or before October 4, 2005 will be considered.
View Prospective Grant of Exclusive License: Adaphostin as a Novel Cancer Therapy Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 3, 2005 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of an Exclusive License: Therapeutics for the Treatment of Kidney Cancer and Thyroid Neoplasms Only written comments and/or license applications which are received by the National Institutes of Health on or before October 3, 2005 will be considered.
View Prospective Grant of an Exclusive License: Anti-Cancer Vaccines Only written comments and/or license applications which are received by the National Institutes of Health on or before October 3, 2005 will be considered.
View Prospective Grant of Exclusive License: Treatment of Inflammatory Diseases Using Ghrelin Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before October 3, 2005 will be considered.
View Prospective Grant of Exclusive License: Use of HIV-Dependent Expression Constructs and Uses Therefor for the Development of FDA-Approvable HIV Diagnostic Kits Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before September 20, 2005 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing and Cooperative Research and Development Agreement (CRADA): Aminoflavone Prodrug
View Prospective Grant of Exclusive License: Mesothelin, a Differentiation Antigen Present on Mesothelium, Mesotheliomas and Ovarian Cancers and Methods and Kits for Targeting Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 12, 2005 will be considered.
View Prospective Grant of Exclusive License: Method for Diagnosis of Atherosclerosis Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before September 6, 2005 will be considered.
View Prospective Grant of Exclusive License: Heat Induced Gene Expression to Treat Cancer Only written comments and/or license applications that are received by the National Institutes of Health on or before September 6, 2005 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Diagnostics of Fungal Infections N/A.
View Government-Owned Inventions; Availability for Licensing
View Opportunity for a Cooperative Research and Development Agreement (CRADA) for Research and Development of Vigabatrin as a Potential Pharmacotherapy for the Treatment of Cocaine and Methamphetamine Dependence NIDA will consider all proposals received within 45 days of the date of publication of this notice. This notice is active until July 5, 2005.
View Prospective Grant of Exclusive License: Peptides Useful in the Treatment of Dyslipidemic and Vascular Disorders Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before July 11, 2005 will be considered.
View Prospective Grant of an Exclusive License: Cancer Diagnostic Based on Detecting Expression of Human Brother of Regulator of Imprinted Sites (“BORIS”) and BORIS Antibodies Only written comments and/or license applications which are received by the National Institutes of Health on or before July 5, 2005 will be considered.
View Prospective Grant of Exclusive License: Use of Human Papilloma Virus (HPV) Immunoreactive Peptides for the Development of Vaccines Against HPV Infections Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before July 5, 2005 will be considered.
View Prospective Grant of Exclusive License: Nitroxides as Protectors Against Oxidative Stress Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 27, 2005 will be considered.
View Prospective Grant of Exclusive License: Human Anesthetic Formulation Based Upon Cyclodextrin Carriers Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before July 19, 2005 will be considered.
View Prospective Grant of Exclusive License: Methods for Treating Inflammatory Bowel Disease Using Cholera Toxin B Subunit Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 14, 2005, will be considered.
View Prospective Grant of an Exclusive License: Therapeutics for the Treatment of Retinopathy Only written comments and/or license applications which are received by the National Institutes of Health on or before June 14, 2005, will be considered.
View Prospective Grant of Exclusive License: Methods for Using Extracellular Adenosine Inhibitors and Adenosine Receptor Inhibitors as Applied to the Treatment of Human Cancer and Tumors Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before June 10, 2005 will be considered.